Clinical Trials Logo

Clinical Trial Summary

The CHARGE-APP project will investigate whether an innovative management strategy of hypertension based on the combination of usual care visits and ESH CARE App compared to standard care, is associated with differences in outcome, including control rate of office, home and ambulatory BP, cardiovascular and renal intermediate end points at one year, and changes in a number of blood pressure-related variables throughout the study.


Clinical Trial Description

CHARGE-APP is a proof-of-concept one-year prospective, randomized, open-label, blinded endpoint study (PROBE) including 2 groups of patients randomized to different treatment strategies: 1. a new management strategy, named POST (i.e. "Patient Optimal Strategy for Treatment"), consisting in providing the patients with a system to communicate home blood pressure measurements to a referral centre, and the referral centre with an online platform to organize and easily interpret the information sent by patients and to monitor the patients' status; 2. usual care, consisting in regular visits at the referral centre. Patients will be enrolled over 3 months and will be randomly allocated to one of the study groups. Follow-up phase will last 12 months after randomization and will focus on changes in ambulatory systolic BP (primary endpoint), in diastolic ambulatory BP, in office SBP and DBP, in Home SBP and DBP, in left ventricular mass index (LVMI) and urinary albumin excretion (UAE), all secondary end-points. All patients will perform visits at baseline, three, six and twelve months. Physical examination, history of the patient and clinical blood pressure values will be obtained at every visit. Echocardiogram, ECG, urine samples (UAE, urinary albumin/creatinine and 24-h ambulatory blood pressure monitoring (ABPM) will be performed at baseline, three months, six months and study end. Blood samples (full blood count, creatinine, Na+, K+, fasting glucose, HbA1c, uric acid, lipids) will be performed at baseline; another blood sample will be collected at twelve months for measurement of serum creatinine (and renal function). UAE will be measured at baseline and study end, on morning urine samples. Patients randomized to POST-strategy will measure Home BP two days a week (two measurements in the morning and two measurements in the evening) and communicate these values with the ESH CARE app; furthermore, before each visit they will measure their Home BP for 7 consecutive days (two measurements in the morning and two measurements in the evening), according to current guidelines on hypertension. Patients randomized to usual care will also measure Home BP for 7 consecutive days at baseline and at study end, to provide a comparison. Operators (i.e. investigators dedicated to the follow-up of POST-strategy) will check these data organized by the POST system at least every 15 days, and adjust pharmacological therapy, if needed. In patients randomized to usual care, therapy will be adjusted only at follow-up visits (i.e. at three and six months). Pharmacological therapy will be increased or decreased according to blood pressure values; investigators may follow a therapy algorithm based on ESH/ESC guidelines, but are free to individualize it. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03206814
Study type Interventional
Source Istituto Auxologico Italiano
Contact Gianfranco Parati, MD
Phone +390261911
Email gianfranco.parati@unimib.it
Status Recruiting
Phase N/A
Start date May 11, 2021
Completion date December 2024

See also
  Status Clinical Trial Phase
Completed NCT05086549 - An Observation Study to Evaluate the Renoprotective Effect of Fimasartan in Patients With DKD and Proteinuria
Recruiting NCT05086523 - Cardiac Neuromodulation Therapy (CNT) "Washout" Sub-Study Phase 1/Phase 2
Active, not recruiting NCT03503773 - The TARGET BP OFF-MED Trial Phase 2
Not yet recruiting NCT04082091 - Screening, Early Referral and Lifestyle Tailored E_prescription for Cardiovascular Prevention
Recruiting NCT06019598 - Licorice and Home Blood Pressure, Additional Study N/A
Completed NCT04495231 - Sympathetic Activity and Cardiometabolic Complications
Completed NCT04119999 - A Cardiosleep Research Program on Obstructive Sleep Apnea, Blood Pressure Control and Maladaptive Myocardial Remodeling N/A
Recruiting NCT04505618 - Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease N/A
Recruiting NCT04863508 - Wearable Blood Pressure Devices to Identify Masked Uncontrolled Hypertension.
Completed NCT05185297 - Recreational Futsal for Controlled Hypertension N/A
Completed NCT03855605 - Diagnosis of Hypertension by Home Blood Pressure Monitoring
Completed NCT03901183 - Plant-based Nutrition for Patients With Cardiovascular Risk Factors N/A
Recruiting NCT04565548 - Hypertension Treatment Adherence Improving Trial N/A
Recruiting NCT06052748 - A Study to Evaluate the Efficacy and Safety of AD-223 Phase 3
Recruiting NCT04613193 - Blood Pressure Reduction in Patients With Asymptomatic Aortic VALVE Stenosis N/A
Completed NCT03841383 - Association Between Coronary Flow Reserve and BH4 Levels in High CV Risk
Recruiting NCT05413057 - An OS to Evaluate Effectiveness and Safety of Fixed-dose Combinations of FMS/AML or FMS/AML/HCTZ
Completed NCT05513430 - Pharmacological and Nonpharmacological Factors That Contribute Blood Pressure Control
Completed NCT04915313 - The Antihypertensive Effect of Remote Ischemic Conditioning (RIC-HTN). N/A
Completed NCT03908710 - The Accumbo Home Blood Pressure Trial N/A